MaxCyte, Inc. (NASDAQ:MXCT - Get Rating) - Stock analysts at William Blair decreased their Q2 2022 EPS estimates for MaxCyte in a report released on Tuesday, May 10th. William Blair analyst M. Larew now expects that the company will post earnings per share of ($0.09) for the quarter, down from their previous forecast of ($0.07). William Blair also issued estimates for MaxCyte's Q3 2022 earnings at ($0.10) EPS, Q4 2022 earnings at ($0.06) EPS, FY2022 earnings at ($0.29) EPS and FY2023 earnings at ($0.27) EPS. MaxCyte (NASDAQ:MXCT - Get Rating) last issued its quarterly earnings data on Tuesday, March 22nd. The company reported ($0.05) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.05). MaxCyte had a negative return on equity of 7.39% and a negative net margin of 41.15%.
Shares of MXCT stock opened at $4.40 on Thursday. The company has a market capitalization of $446.78 million and a P/E ratio of -25.88. The company's 50-day moving average is $5.89. MaxCyte has a 1-year low of $4.00 and a 1-year high of $17.44.
Hedge funds and other institutional investors have recently modified their holdings of the business. Freemont Management S.A. acquired a new stake in MaxCyte in the first quarter worth about $68,000. Nkcfo LLC acquired a new stake in MaxCyte in the first quarter worth about $91,000. Strs Ohio boosted its holdings in MaxCyte by 588.9% in the first quarter. Strs Ohio now owns 24,800 shares of the company's stock worth $173,000 after acquiring an additional 21,200 shares in the last quarter. ProShare Advisors LLC acquired a new stake in MaxCyte in the first quarter worth about $204,000. Finally, Qube Research & Technologies Ltd acquired a new stake in MaxCyte in the first quarter worth about $280,000. 65.86% of the stock is owned by institutional investors and hedge funds.
MaxCyte Company Profile (Get Rating)
MaxCyte, Inc, a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here